ProCE Banner Activity

Targeting Attentional Complaints Across DSM-5 Categories: A Transdiagnostic Approach

Slideset

This presentation on targeting attentional complaints across DSM-5 categories reviews treatments that improve or worsen cognition and holistic strategies to improve cognitive issues in your practice.

Released: March 22, 2022

Expiration: March 21, 2023

No longer available for credit.

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor
Department of Psychiatry
Washington University School of Medicine
President
St. Charles Psychiatry Associates
St. Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Axsome, Corium, Eisai, Ironshore, Intracellular, Janssen, Lumos Labs, Lundbeck, MedPoint, Neos, Neurocrine, Noven, Otsuka, Redax, Roche, Rhodes, Sage, Skye Therapeutics, Sunovion, Supernus, Takeda, Teva, Trispharma; researcher: AbbVie, Acadia, Alkermes, Akilli, Axsome, Boehringer Ingelheim, Corium, Emalex, Idorsida, Janssen, Karuna, Lumos Labs, Medgenics, NLS-1 Pharma AG, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, Teva.